FBT Among Technology ETFs
End-of-day Nov 17, 2026 · 51 Technology ETFs by 1Y
| Returns | Today | 1W | 1M | 3M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| Total return | 0.0% | −1.7% | +0.5% | −1.8% | +29.2% | +33.5% | +98.7% | +65.8% | +202.9% | +1,024.6% |
| Peer average | −1.3% | −4.4% | −9.3% | −12.6% | +1.7% | +3.4% | +64.5% | +20.7% | +365.7% | — |
| S&P 500 · VOO | −1.0% | −2.4% | −4.5% | −4.5% | +8.3% | +10.2% | +72.7% | +68.0% | +305.1% | — |
$46 of every $1,000 in FBT is Genmab
| # | ||||||
|---|---|---|---|---|---|---|
| 1 | GMABGenmab A/S () | Healthcare | 4.62% | $461.69 | 2.7M | $137.4M |
| 2 | ADMAADMA Biologics | Healthcare | 4.32% | $431.51 | 9.5M | $128.5M |
| 3 | REGNRegeneron Pharmaceuticals | Healthcare | 4.23% | $423.39 | 132K | $126.0M |
| 4 | NBIXNeurocrine Biosciences | Healthcare | 3.85% | $385.16 | 694K | $114.7M |
| 5 | ONCBeOne Medicines () | Healthcare | 3.85% | $385.08 | 279K | $114.6M |
| 6 | ARGXargenx SE () | Healthcare | 3.83% | $382.53 | 120K | $113.9M |
| 7 | ALKSAlkermes | Healthcare | 3.80% | $380.26 | 2.4M | $113.2M |
| 8 | TGTXTG Therapeutics | Healthcare | 3.76% | $376.17 | 1.8M | $112.0M |
| 9 | EXELExelixis | Healthcare | 3.72% | $372.02 | 1.7M | $110.8M |
| 10 | BIIBBiogen | Healthcare | 3.70% | $370.02 | 438K | $110.2M |
| 11 | AMGNAmgen | Healthcare | 3.70% | $369.84 | 238K | $110.1M |
| 12 | GILDGilead Sciences | Healthcare | 3.68% | $367.91 | 654K | $109.5M |
| 13 | TARSTarsus Pharmaceuticals | Healthcare | 3.57% | $356.92 | 1.4M | $106.3M |
| 14 | UTHRUnited Therapeutics | Healthcare | 3.55% | $355.28 | 180K | $105.8M |
| 15 | INCYIncyte | Healthcare | 3.54% | $353.89 | 876K | $105.4M |
of the $347B in 58 Technology ETFs
| # | Ticker | Company | Weight ▼ |
|---|---|---|---|
| 1 | GMAB | Genmab A/S () | 4.62% |
| 2 | ADMA | ADMA Biologics | 4.32% |
| 3 | REGN | Regeneron Pharmaceuticals | 4.23% |
| 4 | NBIX | Neurocrine Biosciences | 3.85% |
| 5 | ONC | BeOne Medicines () | 3.85% |
| 6 | ARGX | argenx SE () | 3.83% |
| 7 | ALKS | Alkermes | 3.80% |
| 8 | TGTX | TG Therapeutics | 3.76% |
| 9 | EXEL | Exelixis | 3.72% |
| 10 | BIIB | Biogen | 3.70% |
Estimated yearly cost excludes trading costs and assumes constant assets.
| Ex-date | Paid | Per share |
|---|---|---|
| Dec 13, 2024 | Dec 31, 2024 | $1.17 |
| Dec 30, 2021 | Jan 10, 2022 | $2.21 |
| Sep 23, 2015 | Sep 30, 2015 | $0.0200 |
| Jun 24, 2015 | Jun 30, 2015 | $0.0650 |
| Mar 25, 2015 | Mar 31, 2015 | $0.0480 |
| Dec 23, 2014 | Dec 31, 2014 | $0.0524 |
| Jun 23, 2008 | Jun 30, 2008 | $0.27 |